Promoting Recovery by Overcoming Self-stigma in Mental Health Disorders With a Narrative Enhancement and Cognitive Therapy (NECT) Group Intervention
Promoting Recovery by Overcoming Self-stigma in Mental Health Disorders With a Narrative Enhancement and Cognitive Therapy (NECT) Group Intervention - A Randomized Controlled Trial and Qualitative Study
This study will evaluate whether Narrative Enhancement and Cognitive Therapy (NECT) can promote recovery among adults living with severe mental health disorders, including substance use disorders. NECT is a structured group intervention that combines education about stigma, cognitive techniques to challenge internalized negative beliefs, and narrative exercises that help participants develop a broader identity beyond their diagnosis.
Approximately 106 adults receiving outpatient or day-hospital psychiatric care at Geneva University Hospitals will be randomly assigned to receive either usual care plus 12 weekly NECT sessions or usual care plus 12 comparison group sessions that do not specifically address self-stigma or recovery. The study will examine whether NECT improves recovery after the intervention and whether any benefits are maintained over time.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Self-stigma occurs when people internalize negative societal stereotypes about mental illness. It can contribute to shame, reduced self-esteem, hopelessness, social withdrawal, lower treatment engagement, and difficulties pursuing personal goals. Although recovery-oriented mental health care increasingly emphasizes empowerment, resilience, social inclusion, and quality of life, interventions specifically targeting self-stigma are not yet routinely available. This is particularly relevant for people with substance use disorders, who may experience strong moral judgment and stigmatizing attitudes.
Narrative Enhancement and Cognitive Therapy is a manualized, recovery-oriented group intervention developed to reduce self-stigma. The programme combines psychoeducation about stigma and common misconceptions, cognitive restructuring of negative beliefs about oneself, and narrative exercises in which participants reflect on and share personal experiences. Its purpose is to help participants develop a more integrated understanding of themselves that is not defined solely by mental illness. Previous studies have reported beneficial effects in people with psychotic disorders, but evidence remains limited for other psychiatric populations and for people with substance use disorders. The French-language programme has not yet been evaluated in routine clinical practice.
The study will use a prospective, multicentre, randomized controlled design with an additional qualitative component. Approximately 106 adults with psychiatric disorders will be recruited from three specialized outpatient or day-hospital settings within the Department of Psychiatry at Geneva University Hospitals. Participants will be randomly allocated in a 1:1 ratio to an intervention or control condition. Randomization will be stratified by participating centre.
Participants assigned to the intervention condition will continue their usual psychiatric care and attend 12 weekly NECT group sessions. Participants assigned to the control condition will continue their usual care and attend 12 weekly group sessions that do not include specific psychotherapeutic or psychoeducational content addressing self-stigma or recovery. The comparison sessions may focus, for example, on participants' weekly activities.
NECT will be delivered in groups of approximately eight participants. Each 90-minute session will be facilitated by two trained co-facilitators, including a mental health professional and a peer practitioner. The programme includes an introductory session, psychoeducation, cognitive restructuring, narrative enhancement, and a concluding session. Participants who miss a session may be offered an individual make-up session to review the content and reduce the risk of discontinuing the programme.
The main objective is to determine whether participation in NECT improves personal recovery compared with the control condition. The study will also examine whether any changes are maintained approximately six months after the intervention and whether NECT influences self-stigma, empowerment, quality of life, self-esteem, self-compassion, psychological flexibility, psychiatric symptoms, and substance use.
In addition to the quantitative evaluation, participants who receive NECT may take part in semi-structured interviews after the intervention. These interviews will explore how participants experienced the programme, what they found useful, and how changes in self-stigma may contribute to recovery. The qualitative findings will complement the quantitative results and help inform the possible future implementation of NECT in routine psychiatric and addiction services.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Louise Penzenstadéer, MD
- Número de teléfono: +41223725750
- Correo electrónico: louise.penzenstadler@hug.ch
Copia de seguridad de contactos de estudio
- Nombre: Hélène Richard-Lépouriel, MD
- Número de teléfono: +41223054511
- Correo electrónico: helene.richard-lepouriel@hug.ch
Ubicaciones de estudio
-
-
Canton of Geneva
-
Geneva, Canton of Geneva, Suiza, 1205
- Geneva University Hospital
-
Contacto:
- Louise Penzenstadler, MD
- Número de teléfono: +41223725750
- Correo electrónico: louise.penzenstadler@hug.ch
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Written informed consent
- DSM-5 psychiatric diagnosis within F10-F48, F60-F69, or F90, including substance use disorders
- Receiving outpatient or day-hospital treatment
- Diagnosed or in treatment for at least 12 months
- Clinically stable for at least 3 months, with stable pharmacological treatment during this period
- Clinical Global Impressions-Severity score below 6
Exclusion Criteria:
- Participation in another program likely to affect social functioning or self-stigma, such as social cognitive remediation or social skills training
- Acute psychiatric episode with a Clinical Global Impressions-Severity score above 6
- Medical emergency or immediate life-threatening situation at inclusion
- Unable to provide informed consent
- Comorbid intellectual disability
- Receiving care under constraint or deprived of liberty by judicial order Insufficient ability to speak and read French
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: NECT
Treatment as usual plus 12 weekly 90-minute NECT group sessions combining psychoeducation, cognitive restructuring, and narrative exercises to reduce self-stigma and support recovery.
|
NECT is a manualized group intervention comprising 12 weekly 90-minute sessions delivered to groups of approximately eight participants.
It combines psychoeducation about stigma and self-stigma, cognitive restructuring of internalized negative beliefs, and narrative exercises that help participants develop a more integrated identity beyond mental illness.
Sessions are co-facilitated by a trained mental health professional and a peer practitioner.
Individual make-up sessions may be offered for missed sessions.
|
|
Comparador activo: Control Group
Treatment as usual plus 12 weekly group sessions without specific psychotherapeutic or psychoeducational content targeting self-stigma or recovery
|
Twelve weekly group sessions in which participants discuss topics such as their weekly activities, without specific psychotherapeutic or psychoeducational content targeting self-stigma or recovery.
Treatment as usual continues throughout.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in personal recovery measured by the Recovery Assessment Scale
Periodo de tiempo: Baseline to post-intervention, approximately 12 weeks.
|
Personal recovery will be assessed using the Recovery Assessment Scale (RAS).
The total score ranges up to 205, with higher scores indicating greater recovery.
An increase of at least 14 points is considered clinically meaningful.
|
Baseline to post-intervention, approximately 12 weeks.
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in personal recovery at follow-up
Periodo de tiempo: Baseline to approximately 6 months after the intervention.
|
Personal recovery measured with the Recovery Assessment Scale.
The total score ranges up to 205, with higher scores indicating greater recovery.
An increase of at least 14 points is considered clinically meaningful.
|
Baseline to approximately 6 months after the intervention.
|
|
Change in self-stigma
Periodo de tiempo: Baseline, post-intervention, and approximately 6 months after the intervention.
|
Self-stigma measured with the 29-item Internalized Stigma of Mental Illness Scale.
Items are rated from 1 to 4 and combined into a mean total score ranging from 29 to 116.
The stigma-resistance items are reverse-scored.
Higher scores indicate greater internalized stigma and therefore a worse outcome.
|
Baseline, post-intervention, and approximately 6 months after the intervention.
|
|
Change in empowerment
Periodo de tiempo: Baseline, post-intervention, and approximately 6 months after the intervention.
|
Sense of empowerment measured with the 28-item Empowerment Scale.
an overall mean score will be calculated, ranging from 28 to 112.
Higher scores indicate greater perceived empowerment and therefore a better outcome.
|
Baseline, post-intervention, and approximately 6 months after the intervention.
|
|
Change in quality of life
Periodo de tiempo: Baseline, post-intervention, and approximately 6 months after the intervention.
|
Subjective quality of life measured with the 26-item WHO Quality of Life-BREF.
Scores will be calculated separately for the physical health, psychological health, social relationships, and environment domains and transformed to a scale ranging from 0 to 100.
Higher scores indicate better quality of life and therefore a better outcome.
|
Baseline, post-intervention, and approximately 6 months after the intervention.
|
|
Change in self-compassion
Periodo de tiempo: Baseline, post-intervention, and approximately 6 months after the intervention.
|
Self-compassion measured with the 26-item Self-Compassion Scale.
The total score is ranging from 26 to 130. Higher scores indicate greater self-compassion and therefore a better outcome.
|
Baseline, post-intervention, and approximately 6 months after the intervention.
|
|
Change in psychological flexibility
Periodo de tiempo: Baseline, post-intervention, and approximately 6 months after the intervention.
|
Psychological flexibility measured with the 10-item Acceptance and Action Questionnaire-II.
Items are rated from 1 to 7 and summed to produce a total score ranging from 10 to 70.
Higher scores indicate greater psychological inflexibility and experiential avoidance and therefore a worse outcome.
|
Baseline, post-intervention, and approximately 6 months after the intervention.
|
|
Change in psychiatric symptoms
Periodo de tiempo: Baseline, post-intervention, and approximately 6 months after the intervention.
|
Psychiatric symptoms measured with the 23-item DSM-5 Cross-Cutting Symptom Measure, Levels 1.
It assesses 13 psychiatric symptom domains.
Each item is rated from 0 to 4, and the highest item score within each domain is used as the domain score.
Each domain score therefore ranges from 0 to 4. Higher scores indicate greater symptom frequency or severity and therefore a worse outcome.
There is no single total score for this measure.
The scores should be reported by domain.
|
Baseline, post-intervention, and approximately 6 months after the intervention.
|
|
Change in substance use
Periodo de tiempo: Baseline, post-intervention at approximately 12 weeks, and 6 months after the intervention.
|
Substance use will be assessed using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Level 2-Substance Use.
Each substance-specific item is rated from 0 to 4, where 0 indicates no use and 4 indicates use nearly every day during the previous two weeks.
Higher item scores indicate more frequent substance use and therefore a worse outcome.
Individual substance items will be interpreted separately rather than as a single overall scale score.
|
Baseline, post-intervention at approximately 12 weeks, and 6 months after the intervention.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- in preparation
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .